| Literature DB >> 33025385 |
Marco Gallo1, Valerio Adinolfi2, Viola Barucca3, Natalie Prinzi4, Valerio Renzelli5, Luigi Barrea6, Paola Di Giacinto7, Rosaria Maddalena Ruggeri8, Franz Sesti9, Emanuela Arvat10, Roberto Baldelli7, Emanuela Arvat10, Annamaria Colao, Andrea Isidori, Andrea Lenzi, Roberto Baldell, M Albertelli, D Attala, A Bianchi, A Di Sarno, T Feola, G Mazziotti, A Nervo, C Pozza, G Puliani, P Razzore, S Ramponi, S Ricciardi, L Rizza, F Rota, E Sbardella, M C Zatelli.
Abstract
Obesity, whose prevalence is pandemic and continuing to increase, is a major preventable and modifiable risk factor for diabetes and cardiovascular diseases, as well as for cancer. Furthermore, epidemiological studies have shown that obesity is a negative independent prognostic factor for several oncological outcomes, including overall and cancer-specific survival, for several site-specific cancers as well as for all cancers combined. Yet, a recently growing body of evidence suggests that sometimes overweight and obesity may associate with better outcomes, and that immunotherapy may show improved response among obese patients compared with patients with a normal weight. The so-called 'obesity paradox' has been reported in several advanced cancer as well as in other diseases, albeit the mechanisms behind this unexpected relationship are still not clear. Aim of this review is to explore the expected as well as the paradoxical relationship between obesity and cancer prognosis, with a particular emphasis on the effects of cancer therapies in obese people.Entities:
Keywords: Body mass index; Cancer; Cancer therapy; Obesity; Overweight; Treatment outcome
Mesh：
Year: 2020 PMID： 33025385 DOI： 10.1007/s11154-020-09597-y
Source DB: PubMed Journal: Rev Endocr Metab Disord ISSN： 1389-9155 Impact factor: 6.514